108 related articles for article (PubMed ID: 15203718)
1. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.
Nomura S; Inami N; Iwasaka T; Liu Y
Platelets; 2004 May; 15(3):167-72. PubMed ID: 15203718
[TBL] [Abstract][Full Text] [Related]
2. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus.
Nomura S; Kanazawa S; Fukuhara S
J Hum Hypertens; 2002 Aug; 16(8):539-47. PubMed ID: 12149659
[TBL] [Abstract][Full Text] [Related]
3. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes.
Nomura S; Shouzu A; Omoto S; Hayakawa T; Kagawa H; Nishikawa M; Inada M; Fujimura Y; Ikeda Y; Fukuhara S
Thromb Haemost; 1998 Sep; 80(3):388-92. PubMed ID: 9759615
[TBL] [Abstract][Full Text] [Related]
4. Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines.
Nomura S; Imamura A; Okuno M; Kamiyama Y; Fujimura Y; Ikeda Y; Fukuhara S
Thromb Res; 2000 May; 98(4):257-68. PubMed ID: 10822072
[TBL] [Abstract][Full Text] [Related]
5. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
Cleanthis M; Bhattacharya V; Smout J; Ashour H; Stansby G
Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212
[TBL] [Abstract][Full Text] [Related]
6. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Nomura S; Takahashi N; Inami N; Kajiura T; Yamada K; Nakamori H; Tsuda N
Atherosclerosis; 2004 Jun; 174(2):329-35. PubMed ID: 15136063
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.
Nakamura T; Uchiyama S; Yamazaki M; Iwata M
Thromb Res; 2007; 119(4):511-6. PubMed ID: 17046050
[TBL] [Abstract][Full Text] [Related]
8. [Platelet activation marker].
Nomura S
Rinsho Byori; 2003 Nov; 51(11):1096-101. PubMed ID: 14679788
[TBL] [Abstract][Full Text] [Related]
9. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus.
Omoto S; Nomura S; Shouzu A; Nishikawa M; Fukuhara S; Iwasaka T
Diabetologia; 2002 Apr; 45(4):550-5. PubMed ID: 12032632
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Thromb Res; 2005; 115(4):277-85. PubMed ID: 15668187
[TBL] [Abstract][Full Text] [Related]
11. Elevation of activated platelet-dependent chemokines and soluble cell adhesion molecules in patients with hematologic malignancies and high levels of beta-D-glucan.
Nomura S; Iishii K; Inami N; Kimura E; Urase F
Pathophysiol Haemost Thromb; 2007; 36(1):32-9. PubMed ID: 18332612
[TBL] [Abstract][Full Text] [Related]
12. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
Nomura S; Kanazawa S; Fukuhara S
J Diabetes Complications; 2003; 17(3):153-9. PubMed ID: 12738400
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
14. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
Inoue T; Uchida T; Sakuma M; Imoto Y; Ozeki Y; Ozaki Y; Hikichi Y; Node K
J Am Coll Cardiol; 2004 Oct; 44(7):1408-14. PubMed ID: 15464320
[TBL] [Abstract][Full Text] [Related]
15. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis.
Utsumi K; Kawabe M; Hirama A; Ueda K; Kamada Y; Arii K; Komaba Y; Katsura K; Iino Y; Katayama Y
Clin Chim Acta; 2007 Feb; 377(1-2):198-200. PubMed ID: 17126824
[TBL] [Abstract][Full Text] [Related]
16. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
Nakamura K; Kariyazono H; Masuda H; Sakata R; Yamada K
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):391-7. PubMed ID: 11505083
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.
Li H; Cone J; Fong M; Kambayashi J; Yoshitake M; Liu Y
Cardiovasc Drugs Ther; 2005 Jan; 19(1):41-8. PubMed ID: 15883755
[TBL] [Abstract][Full Text] [Related]
18. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Ito H; Miyakoda G; Mori T
Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
[TBL] [Abstract][Full Text] [Related]
19. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Inami N; Shouzu A; Urase F; Maeda Y
Platelets; 2009 Sep; 20(6):406-14. PubMed ID: 19658004
[TBL] [Abstract][Full Text] [Related]
20. Losartan and simvastatin inhibit platelet activation in hypertensive patients.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
J Thromb Thrombolysis; 2004 Dec; 18(3):177-85. PubMed ID: 15815879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
